Download Specification sheet

Rev: A
Release Date: 12/13/2016
IVD
MDM2 (D-7)
Clone
D-7
Source
MouseMonoclonal
Cat #
Regulatory
Status
Intended use:
PM263-6ml RTU
PM263-3ml RTU
CM263-0.1ml Conc
CM263-0.5ml Conc
HAM263-6ml RTU
HAM263-3ml RTU
IVD
This antibody is intended for use to qualitatively identify MDM2antigen by light microscopy in formalin fixed,
paraffin embedded tissue sections using immunohistochemical detection methodology. Interpretation of any
positive or negative staining must be complemented with the evaluation of proper controls and must be made
within the context of the patient’s clinical history and other diagnostic tests. A qualified
pathologist must perform evaluation of the test.
Summary and Explanation:
p53 is the most commonly mutated gene in human cancer identified to date. Expression of p53 leads to
inhibition of cell growth by preventing progression of cells from G1 to S phase of the cell cycle. Most
importantly, p53 functions to cause arrest of cells in the G1 phase of the cell cycle following any exposure of
cells to DNA-damaging agents. The MDM2 (murine double minute 2) protein was initially identified as an
oncogene in a murine transformation system. MDM2 functions to bind p53 and block p53-mediated
transactivation of cotransfected reporter constructs. The MDM2 gene is amplified in a high percentage of
human sarcomas that retain wildtype p53 and tumor cells that overexpress MDM2 can tolerate high levels of
p53 expression. These findings argue that MDM2 overexpression represents at least one mechanism by which
p53 function can be abrogated during tumorigenesis.
Immunogen:MDM2 (D-7) is a mouse monoclonal antibody raised against amino acids 100-320 of MDM2 of
human origin.
Isotype:
MouseIgG
Reagent Provided:
Concentrated format: Antibody to MDM2is diluted in antibody diluent, with 1% bovine serum
albumin(BSA) and 0.05% sodium azide (NaN3). Recommended dilutions: 1:50 –
1:100.The antibody dilution and protocol may vary depending on the specimen
preparation and specific application. Optimal conditions should be
determined by individual laboratory.
US Office: 538, Selby Lane, Livermore, CA- 94551 USA, Ph: +1 925-218-6939
Corporate Office:CDC Towers, 3rd Floor, B-Block, Plot 10/8, Nacharam IDA, Road #5, Nacharam, Hyderabad-76, India.
Phone: 040-27015544/33,Fax:040-2701 5544 ,
E-Mail:[email protected]: www.pathnsitu.com
Pre-diluted format: PathnSitu ready to use antibodies are pre tittered to optimal staining
conditions. Further dilution may loose the activity and may yield to sub
optimal staining.
Storage Recommendations: Store at 2°-8°C. Do not use after expiration date provided on the vial.
Staining Recommendations:
Antigen Retrieval Solution: Use TrisEDTA(PathnSituCat # PS009) as antigenretrieval solution
Heat Retrieval Method: Retrieve sections under steam pressure for 15 min using
PathnSitu’s MERS (Multi Epitope Retrieval System) then allow solution to cool for
10 minutes then transfer tissue sections/slides to distilled water.
Primary Antibody:
Cover the tissue sections with primary antibody and incubate for 30
min at room temperature when used PathnSituPolyExcel Detection
System.
Detection System: Refer to PathnSituPolyExcel detection system protocol or manufacturer’s
detection kit staining protocol when used other vendor detection system.
Cellular Localization:
Nucleus, Cytoplasm
Positive Control:
Carcinoma Breast, Brain
Troubleshooting:
Follow the antibody specific protocol recommendations according to data sheet
provided. If unusual results occur, contact PathnSitu Technical Support at 0402701 5544 or [email protected]
Limitations and Warranty: There are no warranties, expressed or implied, which extend beyond this
description. PathnSitu is not liable for property damage, personal injury, or
economic loss caused by this product.
Bibliography:
1. White, D.E., et al. 2006. Mouse double minute 2 associates with chromatin in
the presence of p53 and is released to facilitate activation of transcription.
Cancer Res. 66: 3463-3470.
2. Ding, Y., et al. 2006. Interferon-inducible protein IFIXα1 functions as a
negative regulator of HDM2. Mol. Cell. Biol. 26: 1979-1996.
3. Sayan, B.S., et al. 2007. Cleavage of the transactivation-inhibitory domain of
p63 by caspases enhances apoptosis. Proc. Natl. Acad. Sci. USA 104: 1087110876.
4. Iizuka, M., et al. 2008. HBO1 Links p53-dependent stress signaling to DNA
replication licensing. Mol. Cell. Biol. 28: 140-153.
5. Sarafraz-Yazdi, E., et al. 2010. Anticancer peptide PNC-27 adopts an HDM-2binding conformation and kills cancer cells by binding to HDM-2 in their
membranes. Proc. Natl. Acad. Sci. USA 107: 1918-1923.
6. Bom, A.P., et al. 2010. The p53 core domain is a molten globule at low pH:
functional implications of a partially unfolded structure. J. Biol. Chem. 285: 28572866.
7.Ferraz da Costa, D.C., et al. 2012. Transient transfection of a wild-type p53
gene triggers resveratrol-induced apoptosis in cancer cells. PLoS ONE 7:
e48746.
US Office: 538, Selby Lane, Livermore, CA- 94551 USA, Ph: +1 925-218-6939
Corporate Office:CDC Towers, 3rd Floor, B-Block, Plot 10/8, Nacharam IDA, Road #5, Nacharam, Hyderabad-76, India.
Phone: 040-27015544/33,Fax:040-2701 5544 ,
E-Mail:[email protected]: www.pathnsitu.com